Lausanne, Switzerland - Asceneuron SA, an emerging leader in developing novel small molecule therapeutics targeting tauopathies for Alzheimer’s and related neurodegenerative diseases, today announced the appointment of leading experts in the field of neurodegenerative diseases to its newly formed scientific advisory board (SAB): Prof. Christian Haass from Ludwig-Maximilians University (LMU) Munich; Prof. Adam Boxer from University of California, San Francisco (UCSF); and Prof. Günter U. Höglinger from the Technical University of Munich.
